About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
WASHINGTON, D.C. (February 13, 2025) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement after Robert F. Kennedy Jr. was confirmed to serve as the next Secretary for the U.S. Department of Health and Human Services:
“We look forward to working with Secretary Kennedy, the Trump administration, and both parties in Congress to ensure America is stronger, healthier and remains a global leader in biomedical innovation.
“During his confirmation hearings, Secretary Kennedy discussed the need to reduce the burden of chronic disease, improve health outcomes and make health care more affordable for the American people. Our industry is eager to work with the Trump administration to help address these urgent priorities.
“A key part of the solution is to strengthen the ecosystem that makes our country the best place in the world to develop new medicines. American patients have more choices and more access to the most innovative medicines because of policies that encourage risk taking, collaboration and competition. Strengthening the ecosystem by fixing the flaws of government price setting will help us win the global race for medical innovation.
“We also need to rein in abuses that drive up costs at the pharmacy. Half of every dollar spent on medicine goes to middlemen and other entities, and they’re using this windfall to consolidate more control over our health care. Insurers and PBMs are pocketing savings on medicines but making patients pay full price. And hospitals are exploiting the 340B program to charge markups on more medicines while passing the bill to everyone else. Stopping these abuses will lower costs and help people get the care they need."